

CHEMIPHAR AND SUSMED LAUNCH CONCRETE EXAMINATIONS INTO USING BLOCKCHAIN TECHNOLOGIES TO IMPROVE CLINICAL TRIAL EFFICIENCY

Nippon Chemiphar Co., Ltd.
(TSE: 4539)
February 24, 2021

Nippon Chemiphar Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Kazuhiro Yamaguchi, hereinafter, “Chemiphar”) and SUSMED, Inc. (Head Office: Chuo-ku, Tokyo; Representative Director: Taro Ueno, hereinafter, “SUSMED”) hereby announce they have begun concretely examining possible applications of the latter’s blockchain technology for the purposes of raising clinical trial efficiency.

To ensure the quality and reliability of clinical trial data, the Ministerial Ordinance on Good Clinical Practice (GCP) for Drugs requires the comparison of raw data with case report forms (CRFs), known as “monitoring,” when developing pharmaceutical drugs.

This monitoring accounts for a large percentage of total clinical trial costs. Accordingly, interested parties are aggressively seeking means of improving the efficiency of monitoring while maintaining the accuracy and reliability of related data.

SUSMED applies blockchain technologies that confound the illicit efforts of data manipulators and provide higher-level security than conventional methods. At the same time, SUSMED is building highly cost-effective clinical trial systems that enable data management at a guaranteed level of accuracy. The Japanese Minister of Health, Labour, and Welfare and Minister of Economy, Trade, and Industry have stated that if administered properly, these blockchain technologies eliminate the need for on-site monitoring of raw data and CRFs associated with clinical trials, as required by the Ministerial Ordinance on GCP for Drugs.

As a total healthcare group that develops original pharmaceutical drugs and conducts both non-clinical and clinical drug trials, Chemiphar has extensively explored possibilities related to the optimization and streamlining of pharmaceutical development using cutting-edge technologies. As an extension of these practices, Chemiphar has decided to target more productive pharmaceutical drug development by conducting full-scale examinations into possible methods of improving clinical trial efficiency through the application of SUSMED’s blockchain technologies.

For further information contact:

Public Relations Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp